FISH for IgH-FGFR3 Fusion / t(4;14)

A sample of bone marrow or blood is collected. The DNA is then stained with fluorescent probes that bind to the IgH and FGFR3 genes. The sample is analyzed under a fluorescence microscope to detect any abnormalities in these genes.

Individuals diagnosed with or suspected of having multiple myeloma should get this test, as it can provide crucial information regarding the prognosis and guide treatment strategies.

If the FISH test is positive for the IgH-FGFR3 fusion, it means that the t(4;14) translocation is present, which is associated with a more aggressive form of multiple myeloma. This information can be used to develop a targeted treatment plan.

No, there are other methods such as karyotyping and PCR, but FISH is particularly sensitive and specific for detecting genetic changes including t(4;14) translocation.

A positive result indicates the presence of t(4;14) translocation and suggests a higher risk or aggressiveness of multiple myeloma, but the diagnosis should be confirmed with additional tests and clinical assessment.

No specific preparation is required for this test. However, you should follow any instructions provided by your doctor.

Yes, a positive test for IgH-FGFR3 fusion indicates that targeted therapies might be beneficial in treating the disease.

The test’s results can be affected by the quality of the sample, the presence of interfering substances, and technical factors related to the FISH procedure.

A family history of multiple myeloma can be a risk factor. It’s advisable to discuss any concerns with your doctor who can guide you regarding any necessary tests or monitoring.

FISH is generally considered to be a highly reliable and accurate method for detecting genetic abnormalities such as the IgH-FGFR3 fusion.

The test involves drawing blood or bone marrow, which carries minimal risks such as bleeding, bruising, or infection at the puncture site.

Coverage for the FISH test varies depending on your insurance plan. It's advisable to check with your insurance provider to determine if this test is covered.

If the test is positive, it is important to discuss the results with your doctor to understand the implications and to determine the most appropriate treatment strategy.

This FISH test for IgH-FGFR3 Fusion is essential in the management of patients with multiple myeloma. It provides valuable information on the genetic makeup of the cancer, which can be crucial for prognosis and treatment planning. Patients should actively communicate with their doctors to understand the significance of the test results and to make informed decisions regarding their care.